Once used, does anamorelin need to be taken for life? Dosing cycles and discontinuation guidelines during treatment

Anamorelin is a drug used to treat loss of appetite and cachexia caused by cancer. It is often used to relieve weight loss and malnutrition caused by malignant tumors. The drug increases appetite, increases food intake, and improves weight by activating insulin-like growth factor 1 (IGF-1) receptors. Therefore, it is mainly used to improve the nutritional status of cancer patients, especially those who have experienced significant weight loss. However, the use of anamorelin does not require lifelong use, and the treatment cycle will be adjusted based on the patient's specific condition and treatment response.

Anamorelin is usually used for several months during treatment, and the specific duration depends on the patient's weight, appetite, and improvement in nutritional status. When patients receive anamorelin, their doctors will regularly evaluate its efficacy and side effects. If the patient's weight stabilizes and his appetite gradually improves, the doctor may gradually reduce the dose of the drug or even discontinue it. During the follow-up period after drug withdrawal, doctors will continue to monitor the patient's weight and appetite to ensure that cachexia symptoms have not returned.

The timing of discontinuation depends on the patient's specific condition. For those patients who are well controlled, anamorelin may be gradually discontinued, but the patient's weight and nutritional status still need to be closely monitored. Treatment may need to be restarted if symptoms such as weight loss or loss of appetite return.

In general, the use of anamorelin is not lifelong. The treatment cycle is adjusted according to changes in the patient's condition. Discontinuation of the drug needs to be done under the guidance of a doctor to ensure that the treatment effect continues and the patient's nutritional status remains stable.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/